Internal Medicine

Are most people who show mild sensitivity to bee venom a sting away from developing systemic allergies and suffering anaphylaxis? New research suggests the answer is no, but they are in danger of serious reactions at the sting site.

Severe coronary calcification is an independent predictor of worse prognosis in obstructive coronary artery disease patients undergoing percutaneous coronary intervention.

Patients with chronic obstructive pulmonary disease are twice as likely to develop mild cognitive impairment.

Schizophrenia is typically caused by damage to several genes, rather than a single genetic mutation.

The newer non-ergoline-derived dopaminergic agents appear to cause only minimal endocrine effects when used to treat idiopathic Parkinson's disease.

Findings from a pair of ongoing studies into the effects of testosterone replacement therapy indicate unexpected significant improvements for obese patients.

Depression affects one in 3 patients with critical illness like respiratory failure or severe sepsis, according to research published in The Lancet Respiratory Medicine.

Taking more than 5 medications was associated with fatigue and memory problems in multiple sclerosis patients, a new study reports.

Although previous studies have suggested married people are generally happier and healthier, new research has discovered marital stress increases their vulnerability to depression.

People from the Baby Boom generation covered under Medicare can now get one-time screening for hepatitis C, according to a memo from the Centers for Medicare & Medicaid Services.

Prebiotics and probiotics have been discussed frequently in the media for supposedly improving overall health, especially diseases related to the gut. However, the evidence on the efficacy and use of these dietary supplements is rather complicated.

After studying an Amish population, researchers at the University of Maryland Medical Center have discovered a mutation in a fat-storage gene that increases a patient's risk for type 2 diabetes.

A new study in mice of the multiple sclerosis drug fingolimod (Gilenya) suggests the drug may be a new therapeutic target for a treatment of post-traumatic stress and other anxiety disorders.

A new study indicates that treating hyperlipidemia, glucose intolerance, high blood pressure, sleep apnea, and other risk factors associated with atrial fibrillation can dramatically reduce the burden of the disease or eliminate it entirely.

When testing patients for HIV, healthcare professionals should also test for sexually transmitted infections.

In this issue of Cardiology Review, we cover several burning topics of interest to clinicians.

The first wireless implantable hemodynamic monitoring system for patients with heart failure has been approved by the FDA.

The American Society of Hypertension (ASH) is the largest US professional organization dedicated to eradicating hypertension and its consequences. The following study presentations were highlights of the organization's 29th annual meeting in New York City.

AstraZeneca's Epanova (omega-3-carboxylic acids) was approved by the FDA for the treatment of adults with severe hypertriglyceridemia; two new studies support the concept that there can be too much of a good thing when it comes to exercise; and the FDA has issued a new statement recommending against the use of aspirin to prevent a first heart attack or stroke in people with no history of cardiovascular disease.

Should we give digoxin another look for chronic heart failure?

The safety and efficacy of drug-eluting stents are proven in the general population, but how do they perform in women?

Internists must resist taking as much as they can carry from the current healthcare system just because they can get away with it.

The behavior of a particular prion-like protein is associated with Alzheimer's disease (AD) and several other neurodegenerative disorders.

Experts examine conflicting evidence regarding the continuation of disease-modifying therapy in patients with secondary progressive multiple sclerosis.

Session at the 2014 Annual Meeting of the Consortium of Multiple Sclerosis Centers debates whether the side effects associated with alemtuzumab, a novel anti-CD52 monoclonal antibody, might ultimately prevent its approval for the treatment of multiple sclerosis, despite evidence of clinical effectiveness.

Low rates of immunogenicity observed in study support the potential benefits of subcutaneous peginterferon beta-1a in the treatment of patients with relapsing-remitting multiple sclerosis.

The reductions in brain volume often seen in patients with chronic relapsing–remitting multiple sclerosis may be reduced by treatment with interferon beta-1a, though treatment may be affected by the patient's immunologic status.

Analysis of NARCOMS data showed that switching from natalizumab to fingolimod or injectable therapy was associated with an increased likelihood of reported disability progression.